Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 3/20 | 0.37 |
| ▸ | ESR1 | P03372 | 3/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 8/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CCL2 | P13500 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4857357 | 0.91 | ESR1 (0.37) | THRATHRBESR1ESR2MEN1 | |
| SCHEMBL4858909 | 0.80 | ESR2 (0.54) | ESR1ESR2 | |
| SCHEMBL6150367 | 0.71 | ESR2 (0.39) | THRATHRBESR1ESR2MEN1 | |
| SCHEMBL4854661 | 0.67 | ESR2 (0.55) | ESR1ESR2MEN1NPC1ALDH1A1 | |
| SCHEMBL4859486 | 0.63 | ESR2 (0.60) | ESR1ESR2 | |
| SCHEMBL6151438 | 0.63 | ESR2 (0.58) | THRATHRBESR1ESR2 | |
| SCHEMBL31261902 | 0.62 | TIPARP (0.42) | ALDH1A1MAPTKMT2A | |
| SCHEMBL31261900 | 0.62 | TIPARP (0.42) | ALDH1A1MAPTKMT2A | |
| SCHEMBL4815741 | 0.62 | MAOB (0.63) | — | |
| SCHEMBL14926627 | 0.62 | CA12 (0.51) | THRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432284-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20060041003-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041003-A1 | Estrogen receptor modulators | GPER1, ESR2, ESR1 | THRA 406/4885THRB 584/4885ESR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.